| Nov 21 |
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
|
| Nov 20 |
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
|
| Nov 20 |
NewAmsterdam Pharma says late-stage trial for cholesterol drug succeeded
|
| Nov 20 |
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
|
| Nov 18 |
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
|
| Nov 11 |
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
|
| Nov 6 |
NewAmsterdam Pharma GAAP EPS of -$0.18 beats by $0.31, revenue of $29.11M
|
| Nov 6 |
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
|
| Oct 8 |
Three Undervalued Small Caps In United States With Insider Buying To Consider
|
| Oct 7 |
Insider Buying Highlights These 3 Undervalued Small Caps In United States
|
